Products Daptomycin
Daptomycin Pre-clinical Terminated 💤 Quiet May 1, 2010 → May 1, 2011
About Daptomycin Daptomycin is a pre-clinical stage product being developed by Merck for Meningitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01025271. Target conditions include Meningitis.
Clinical Trials (15) NCT ID Phase Status Start Completion Indication NCT01025271 Pre-clinical Terminated May 1, 2010 May 1, 2011 Meningitis NCT01019395 Phase 1 Completed Jan 5, 2010 Mar 20, 2012 Gram Positive Bacterial Infection NCT01012089 Pre-clinical Completed Nov 1, 2009 Apr 1, 2014 Chronic Kidney Disease NCT00701636 Phase 3 Completed Jul 1, 2008 Oct 1, 2010 Late Effects of Surgery NCT00679835 Phase 1 Completed Jun 3, 2008 Nov 20, 2008 Gram Positive Infection NCT00490737 Phase 1 Completed Aug 12, 2007 May 12, 2008 End-Stage Renal Disease NCT00467272 Phase 2 Completed Mar 1, 2007 Sep 1, 2012 Bloodstream Infection NCT00663403 Approved Completed Feb 1, 2007 Apr 1, 2009 Critically Ill NCT00507247 Phase 2 Completed May 1, 2006 Sep 1, 2012 Staphylococcus Aureus NCT00136292 Phase 1 Completed Aug 24, 2005 Aug 9, 2006 Gram-positive Bacterial Infections NCT00651131 Approved Terminated Jun 1, 2004 Mar 1, 2005 Wound Infections NCT00055198 Phase 3 Terminated Dec 19, 2002 Jan 26, 2004 Gram-Positive Bacterial Infections NCT00093067 Phase 3 Completed Mar 1, 2002 Feb 1, 2005 Bacterial Endocarditis NCT00540072 Phase 3 Completed Jul 30, 2001 Feb 27, 2002 Pneumonia, Bacterial NCT00538694 Phase 3 Completed Oct 31, 2000 Sep 30, 2001 Pneumonia, Bacterial
Product Company Stage Hype Score RotaTeq® + NeisVac-C® Merck Phase 3 Meningococcal ACWY conjugate vaccine Novartis Phase 3 Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine Novartis Approved Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP Novartis Phase 3 Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and Menveo Novartis Phase 3 Meningococcal ACWY conjugate vaccine Novartis Phase 3 MenACWY-CRM + MenC-CRM + DTaP-Hib-IPV + PC7 + MMR + Varicella Novartis Phase 2 Hib-CRM197 + Hib-TT Novartis Phase 3 Novartis Meningococcal ACWY Conjugate Vaccine + Tdap Vaccine + Novartis Meningococcal ACWY Conjugate Vaccine Novartis Phase 3 MenACWY-CRM conjugate vaccine, adjuvanted + MenACWY polysaccharide vaccine + MenACWY-CRM conjugate vaccine, unadjuvanted Novartis Phase 2 meningococcal B vaccine & meningococcal ACYW conjugate vaccine Novartis Phase 2 Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine Novartis Phase 2 4CMenB Novartis Approved Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine Novartis Phase 3 Meningococcal (group B) multicomponent recombinant adsorbed vaccine Novartis Phase 3 MenACWY-CRM197 (two doses) + MenC + PCV7 + DTPa-IPV-HepB-Hib + MenACWY-CRM197 (one dose) Novartis Phase 3 MenACWY-CRM197 + DTaP (Diptheria, Tetanus, Pertussis) Vaccine + Hib (Haemophilus influenza b) Vaccine + IPV (Inactivated Polio Vaccine) Vaccine + Pneumococcal conjugate Vaccine + MMR (Measles, Mumps, and Rubella) Vaccine + Varicella Vaccine + Hepatitis A Virus Novartis Phase 3 Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years) Novartis Phase 3 Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Control + Meningococcal B vaccine with antipyretic Novartis Phase 2 Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1) + Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2) + Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3) + Infanrix Hexa + Menjugate + Prevenar Novartis Phase 3
Other Products from Merck